6/ Immunotherapy is the major advance in myeloma. Bispecific antibodies and CAR-T cell therapy hold great promise. Multiple options available for myeloma refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, isatuximab, alkylators, and transplant. pic.twitter.com/BoeeYgYzHe
— Vincent Rajkumar (@VincentRK) June 12, 2021